Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Brainstorm Cell Therapeutics (BCLI)
NASDAQ:BCLI
RESEARCH TOOLSreports
Holding BCLI?
Track your performance easily
Earnings Data
Report Date
Mar 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.27Last Year’s EPS
-$1.66Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2024
|% Change Since: 109.73%
|Next Earnings Date:Mar 27, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted several positive developments, including progress in clinical trials, financial improvements, and strategic partnerships. However, challenges remain with NASDAQ compliance and potential dilution concerns. Overall, the sentiment indicates cautious optimism with a focus on overcoming existing challenges.Company Guidance
During the BrainStorm Cell Therapeutics Q2 2024 earnings call, the company provided guidance on several key metrics reflecting its financial and operational progress. As of June 30, 2024, the company reported cash, cash equivalents, and restricted cash of approximately $3.65 million, up from $0.75 million a year earlier. Research and development expenses for Q2 2024 were about $0.9 million, down from $2.8 million in Q2 2023, while general and administrative expenses decreased to $2 million from $2.7 million. The net loss for Q2 2024 was approximately $2.5 million, compared to a net loss of $5.3 million in the same quarter the previous year, translating to a net loss per share of $0.04 versus $0.13. The company also highlighted its strategic focus on securing up to $15 million in nondilutive funding and emphasized its commitment to meeting NASDAQ listing requirements, including maintaining a $1 share price for 10 consecutive trading days by October 28, and achieving a $35 million market cap.Progress in Phase IIb Trial for NurOwn in ALS
BrainStorm Cell Therapeutics is making substantial progress in preparations for the Phase IIb trial for NurOwn in ALS, with a written SPA agreement secured from the FDA.
Financial Position Strengthened
Cash, cash equivalents, and restricted cash increased to approximately $3.65 million as of June 30, 2024, compared to $0.75 million as of June 30, 2023.
Reduction in Net Loss
Net loss for the 3 months ended June 30, 2024, was approximately $2.5 million, compared to a net loss of approximately $5.3 million for the 3 months ended June 30, 2023.
Pursuit of Nondilutive Funding
Actively pursuing nondilutive funding, including a promising grant application with the potential to secure up to $15 million.
Alignment with FDA on CMC Aspects
Reached alignment with FDA on CMC aspects of the Phase III trial during a Type C meeting.
---
BCLI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BCLI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $1.13 | $1.21 | +7.08% |
| Aug 14, 2024 | $4.78 | $4.58 | -4.18% |
| May 14, 2024 | $7.50 | $7.26 | -3.20% |
| Apr 01, 2024 | $8.47 | $11.10 | +31.05% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Brainstorm Cell Therapeutics (BCLI) report earnings?
Brainstorm Cell Therapeutics (BCLI) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.
What is Brainstorm Cell Therapeutics (BCLI) earnings time?
Brainstorm Cell Therapeutics (BCLI) earnings time is at Mar 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BCLI EPS forecast?
BCLI EPS forecast for the fiscal quarter 2024 (Q4) is -$0.27.
---